+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      T1 and ECV Mapping in Myocardial Disease

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          T1 mapping using cardiovascular magnetic resonance (CMR) introduces novel techniques for myocardial tissue characterization to detect and quantify disease processes occurring at the microscopic level. Even though T1 mapping has limited spatial resolution, cellular and molecular changes occurring within each voxel can affect the aggregate T1 signal rendering them quantifiable. The estimated T1-based parameters quantified on a “map” demonstrate the spatial localization of these changes whereby each pixel expresses the quantitative value of that parameter. This quantification permits detection of diffuse disease even if it is not directly visible. Rather than relying on nonspecific functional measures, T1 mapping focuses on intrinsic changes of myocardial composition that advances understanding about specific disease pathways. These changes in myocardial tissue composition inform diagnosis and prognosis. T1 mapping encompasses two key parameters: native (i.e., precontrast) T1 and extracellular volume fraction (ECV) derived from additional postcontrast T1 and blood T1 measurements. These advances introduce new tools to detect focal and diffuse myocardial derangements occurring in cardiac disease that can be otherwise difficult to detect. T1 and ECV mapping foster precision medicine and personalized care, promising to improve patient outcomes through targeted therapy. Capitalizing on the opportunities introduced by T1 mapping and ECV requires further investigation.

          Related collections

          Most cited references 97

          • Record: found
          • Abstract: found
          • Article: not found

          Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance.

          Systemic sclerosis (SSc) may induce cardiac fibrosis and systo-diastolic dysfunction. Cardiovascular magnetic resonance (CMR) can detect replacement myocardial fibrosis with late gadolinium enhancement (LGE) and interstitial myocardial fibrosis with T1 mapping techniques. The aim of the study was to detect subclinical cardiac involvement with CMR in paucisymptomatic SSc patients with no previous history of myocardial disease, comparing it with skeletal muscle remodelling.
            • Record: found
            • Abstract: not found
            • Article: not found

            Fibrosis--A Common Pathway to Organ Injury and Failure

              • Record: found
              • Abstract: found
              • Article: not found

              Interstitial Fibrosis, Functional Status, and Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From a Prospective Cardiac Magnetic Resonance Imaging Study.

              Myocardial extracellular volume (ECV) accumulation is one of the key pathophysiologic features of heart failure with preserved ejection fraction (HFpEF). Our aims were to (1) measure ECV by cardiac magnetic resonance T1 mapping using the modified Look-Locker inversion recovery (MOLLI) sequence, (2) validate MOLLI-ECV against histology, and (3) investigate the relationship between MOLLI-ECV and prognosis in HFpEF.

                Author and article information

                1Department of Clinical Physiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
                2Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
                3UPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, PA, USA
                4Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA
                Author notes
                Correspondence: Erik B. Schelbert, MD, MS, Director, Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, UPMC, Pittsburgh, PA, USA; and Assistant Professor of Medicine and Clinical and Translational Science, University of Pittsburgh School of Medicine, 200 Lothrop Street, PUH A349, Pittsburgh, PA 15101, USA, Tel.: 412-647-5840, Fax: 412-647-4227, E-mail: schelberteb@
                Cardiovascular Innovations and Applications
                Compuscript (Ireland )
                March 2017
                March 2017
                : 2
                : 1
                : 73-84
                cvia20160066 10.15212/CVIA.2016.0066
                Copyright © 2017 Cardiovascular Innovations and Applications

                This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See



                Comment on this article